SCHEMBL17832808

SCHEMBL17832808

CCNC(=O)CN(C)C(=O)OC(C)(C)C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA14 Q9ULX7 2/20 0.36
PRSS1 P07477 1/20 0.35
TPSAB1 Q15661 1/20 0.35
CAPN1 P07384 1/20 0.35
MCL1 Q07820 1/20 0.33
HDAC6 Q9UBN7 2/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA7 P43166 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC2 Q92769 1/20 0.33
FAAH O00519 1/20 0.32
AHCY P23526 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
CTSD P07339 1/20 0.31
CTSL P07711 1/20 0.31
CTSB P07858 1/20 0.31
CTSS P25774 1/20 0.31
DGAT1 O75907 1/20 0.31
CHRNB2 P17787 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2586333 0.94 CAPN1 (0.33) CA14PRSS1TPSAB1CAPN1MCL1
SCHEMBL13934339 0.83 CA14 (0.41) CA14FAAHTDP1MEN1GAA
SCHEMBL2589264 0.83 RECQL (0.46) CA14PRSS1TPSAB1HDAC6CA12
SCHEMBL7174226 0.83 CA14 (0.34) CA14PRSS1TPSAB1HDAC6HDAC1
SCHEMBL1105464 0.81 HDAC6 (0.34) CA14PRSS1TPSAB1HDAC6CA12
SCHEMBL6526008 0.81 HDAC6 (0.34) CA14PRSS1TPSAB1HDAC6CA12
SCHEMBL13921016 0.81 SIGMAR1 (0.39) CA14PRSS1TPSAB1HDAC6HDAC1
SCHEMBL8572055 0.81 PRSS1 (0.39) CA14PRSS1TPSAB1HDAC6CA1
SCHEMBL23418344 0.81 CA14 (0.41) CA14CAPN1MCL1HDAC6CA12
SCHEMBL850511 0.80 SMN1; SMN2 (0.41) CA14PRSS1TPSAB1HDAC6FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250145628-A1 PYRAZOLOPYRIMIDINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF NOVO NORDISK A/S (DK) 2025-05-08 US disclosed
CN-119301126-A Pyrazolopyrimidine compound, composition containing pyrazolopyrimidine compound and application of pyrazolopyrimidine compound 诺和诺德股份有限公司 2025-01-10 CN disclosed
EP-4479402-A1 PYRAZOLOPYRIMIDINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF Novo Nordisk A/S (DK) 2024-12-25 EP disclosed
WO-2023155004-A1 PYRAZOLOPYRIMIDINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF INVERSAGO PHARMA INC. (CA) 2023-08-24 WO disclosed
WO-2022150574-A1 INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE CORNELL UNIVERSITY (US) 2022-07-14 WO disclosed
EP-3230274-B1 NOVEL ARYL-CYANOGUANIDINE COMPOUNDS Bayer Pharma AG (DE) 2019-01-30 EP disclosed
WO-2016091845-A1 NOVEL ARYL-CYANOGUANIDINE COMPOUNDS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250145628-A1 PYRAZOLOPYRIMIDINES, COMPOSITIONS COMPRISING THEM AND USES THEREOF CNR1, CNR2, TRPV1 CA14 3705/4885PRSS1 1558/4885TPSAB1 1290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.